Comparative analysis of fingolimod versus teriflunomide in relapsing-remitting multiple sclerosis


BOZ C., TERZİ M., Ozer B., Turkoglu R., KARABUDAK R., EFENDİ H., et al.

MULTIPLE SCLEROSIS AND RELATED DISORDERS, cilt.36, 2019 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 36
  • Basım Tarihi: 2019
  • Doi Numarası: 10.1016/j.msard.2019.101376
  • Dergi Adı: MULTIPLE SCLEROSIS AND RELATED DISORDERS

Özet

Background: Fingolimod and teriflunomide are commonly used in the treatment of relapsing-remitting multiple sclerosis (RRMS). These have not been compared in controlled trials, but only in observational studies, with inconclusive results. Comparison of their effect on relapse and disability in a real-world setting is therefore needed.